Filing Details
- Accession Number:
- 0001415889-25-002003
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-23 20:36:55
- Reporting Period:
- 2025-01-23
- Accepted Time:
- 2025-01-23 20:36:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1680739 | D. Roy Baynes | C/O Travere Therapeutics, Inc. 3611 Valley Centre Dr., Suite 300 San Diego CA 92130 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2025-01-23 | 16,000 | $17.50 | 47,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2025-01-23 | 16,000 | $20.00 | 31,000 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (right to buy) | Disposition | 2025-01-23 | 16,000 | $0.00 | 16,000 | $17.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2026-07-19 | No | 4 | M | Direct |
Footnotes
- This sale was made pursuant to a written plan adopted on August 16, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on July 19, 2016, with an expiration date of July 19, 2026.
- The stock option is fully vested and exercisable.